Dementia is a condition that affects memory, thinking, and the ability to perform everyday tasks. As it progresses, it can ...

Consequently, combination therapy currently involves the administration of one cholinergic drug (donepezil, galantamine or rivastigmine) and one glutamatergic drug (memantine). There have been no ...

This article looks at the rationale behind the combined use of acetylcholinesterase inhibitors and the N-methyl-D-aspartate-receptor antagonist, memantine, from both preclinical and clinical ...

Our NICE Advice service will guide you there. Get reliable scientific advice and NHS insights, direct from NICE. We support companies seeking nationwide adoption of the best treatments and care. Our ...

Donepezil (Aricept) was approved in 1996, Rivastigmine (Exelon) was approved in 2000, and galantamine (Reminyl) was approved in 2001. In October, 2003, the FDA approved Memantine (Namenda) for the ...

ZUNVEYL's active metabolite is differentiated from donepezil and rivastigmine in that it improves the function of neuronal nicotinic receptors, most notably the alpha-7 subtype, which is known to have ...